Earnings Scorecard & Analyst Reports NASDAQ:CLRB, NASDAQ:PHAS, NASDAQ:HEPA, NASDAQ:AMTX

CELLECTAR BIOSCIENCES (NASDAQ:CLRB) EARNINGS INFORMATION (NASDAQ:CLRB)

Cellectar Biosciences last posted its earnings results on August 8th, 2021. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11). Cellectar Biosciences has generated ($0.76) earnings per share over the last year (($0.61) diluted earnings per share). Earnings for Cellectar Biosciences are expected to decrease in the coming year, from ($0.46) to ($0.49) per share. Cellectar Biosciences has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, November 8th, 2021 based off prior year’s report dates.

IS CELLECTAR BIOSCIENCES A BUY RIGHT NOW? (NASDAQ:CLRB)

3 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Cellectar Biosciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” Cellectar Biosciences stock.
Cellectar Biosciences

PHASEBIO PHARMACEUTICALS (NASDAQ:PHAS) EARNINGS INFORMATION (NASDAQ:PHAS)

PhaseBio Pharmaceuticals last announced its earnings data on August 12th, 2021. The reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by $0.14. PhaseBio Pharmaceuticals has generated ($3.39) earnings per share over the last year (($3.74) diluted earnings per share). Earnings for PhaseBio Pharmaceuticals are expected to remain at ($2.47) per share in the coming year. PhaseBio Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 11th, 2021 based off prior year’s report dates.

IS PHASEBIO PHARMACEUTICALS A BUY RIGHT NOW? (NASDAQ:PHAS)

2 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for PhaseBio Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” PhaseBio Pharmaceuticals stock.
PhaseBio Pharmaceuticals

HEPION PHARMACEUTICALS EARNINGS ESTIMATES AND ACTUALS BY QUARTER (NASDAQ:HEPA)

WHAT STOCKS DOES MARKETBEAT LIKE BETTER THAN HEPION PHARMACEUTICALS? (NASDAQ:HEPA)

Wall Street analysts have given Hepion Pharmaceuticals a “N/A” rating, but there may be better buying opportunities in the stock market. Some of MarketBeat’s past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Hepion Pharmaceuticals wasn’t one of them. MarketBeat thinks these five companies may be even better buys.

AEMETIS (NASDAQ:AMTX) EARNINGS INFORMATION (NASDAQ:AMTX)

Aemetis last issued its quarterly earnings data on August 11th, 2021. The specialty chemicals company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.08. Aemetis has generated ($1.74) earnings per share over the last year (($1.86) diluted earnings per share). Earnings for Aemetis are expected to grow in the coming year, from ($2.00) to ($1.73) per share. Aemetis has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 11th, 2021 based off prior year’s report dates.

IS AEMETIS A BUY RIGHT NOW? (NASDAQ:AMTX)

8 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Aemetis in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” Aemetis stock.
Aemetis